Purpose: Diffuse and nodular forms of mantle-cell lymphoma (MCL) are consistently associated with poor prognosis. In an effort to improve the outcome, we adopted a treatment plan that consisted of four courses of fractionated cyclophosphamide (CY) 1,800 mg/m 2 administered with doxorubicin (DOX), vincristine (VCR), and dexamethasone (Hyper-CVAD) that alternated with high-dose methotrexate (MTX) and cytarabine (Ara-C). After four courses, patients were consolidated with high-dose CY, total-body irradiation, and autologous or allogeneic blood or marrow stem-cell transplantation.
al l°' recently showed that the mantle zone variant is relatively favorable with a natural history similar to indolent lymphoma, but the diffuse and nodular forms are associated with a poor response to treatment. In their study, only 20% of the patients with diffuse histology achieved a complete remission with a cyclophosphamide (CY), doxorubicin (DOX), vincristine (VCR), and prednisone (CHOP)-like regimen, with a 3-year freedom from disease progression rate of only 26%. High-dose chemoradiotherapy is an effective form of treatment for relapsed non-Hodgkin's lymphoma. 1 ' Recent reports suggest that high-dose therapy and stem-cell transplantation may improve the outcome of poor-prognosis intermediate-grade lymphoma patients aged younger than 60 years when used as first remission consolidation. 12 on to undergo transplantation achieved CRs. For the 25 previously untreated patients, the overall survival (OS) and event-free survival (EFS) rates at 3 years were 92% (95% confidence interval [CI], 80 to 100) and 72% (95% CI, 45 to 98) compared with 25% (95% Cl, 12 to 62; P = .005) and 17% (95% Cl, 10 to 43; P = .007), respectively, for the previously treated patients. When compared with a historic control group who received a CY, DOX, VCR, and prednisone (CHOP)-like regimen, untreated patients in the study had a 3-year EFS rate of 72% versus 28% (P = .0001) and a better OS rate (92% v 56%; P = .05). Treatment-related death occurred in five patients: all were previously treated and two received allogeneic transplants.
Conclusion: The Hyper-CVAD/MTX-Ara-C program followed by stem-cell transplantation is a promising new therapy for previously untreated patients with MCL.
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Effective induction chemotherapy is needed to reduce the tumor burden and clear the marrow involvement to allow stem-cell collection for autologous transplantation for patients with nodular or diffuse forms of MCL. We evaluated the effectiveness of a regimen that consisted of four courses of fractionated CY administered with DOX, VCR, and dexamethasone (Hyper-CVAD) that alternated with sequential high-dose methotrexate (MTX) and cytarabine (Ara-C). This regimen was selected based on its demonstrated activity in pediatric' 3 and adultl4 patients with acute lymphoblastic leukemia (ALL). After four courses, patients received high-dose chemoradiotherapy with autologous or allogeneic stem-cell transplantation.
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PATIENTS AND METHODS
Patient Eligibility
Adult patients aged 65 years or younger with poor-risk MCL (diffuse, nodular) previously untreated or at relapse were studied. Patients were required to have a good performance status (Zubrod ' 2) with no severe concomitant medical or psychiatric illnesses. Patients with any of the following were ineligible: CNS involvement, positive HIV serology, bilirubin level greater than 1.5 mg/dL, cardiac ejection fraction less than 50%, or pulmonary function test and lung-diffusing capacity less than 50% of predicted levels. Informed consent was obtained from all patients, and the treatment protocol was approved by the Institutional Review Board of the University of Texas M.D. Anderson Cancer Center.
Clinical Evaluation
Disease stage was evaluated in accordance with Ann Arbor criteria 1s and assigned a tumor score in accordance with the M.D. Anderson Lymphoma Tumor Score System. 1 6 Patients underwent the following staging procedures: physical examination, complete blood count with differential, serum chemistry panel, serum 3 2 -microglobulin level, chest radiography, computed tomography of the abdomen and the pelvis, and bilateral bone marrow aspiration and biopsy. In addition, patients with gastrointestinal symptoms underwent endoscopy screening for lymphomatous involvement.
Pathologic Evaluation
All cases were reviewed by an expert hematopathologist (W.C.P.) for diagnostic confirmation. Each case was further subclassified with regard to growth pattern as follows: nodular, in which centripetal as well as centrifugal expansion of the neoplastic mantle obliterated the central germinal center in at least 90% of the nodules, which resulted in the loss of an easily discernible mantle zone configuration; and diffuse, in which confluent growth effaced nodal architecture as well as residual nodularity. Patients with mantle zone variant, in which neoplastic cells proliferated as wide collars about reactive germinal centers, were not eligible for this study.
Immunophenotypic studies were performed by flow cytometry or by in situ immunohistochemistry that used standard techniques and antibodies to the following cluster antigens: CD2, CD3, CD5, CD7, CDIO0, CD19, CD20, CD23, CD43, and CD79a. Polyclonal antibodies to K and k light chains and cyclin Dl (the last of these kindly provided by Dr Lawrence Zukerberg ) were also used.
Induction Chemotherapy
The treatment schema is shown in Fig 1. The initial course of chemotherapy consisted of intravenous (IV) CY 300 mg/m 2 every 12 hours for six doses, plus DOX 50 mg/m 2 over 48 hours and VCR 2 mg administered 12 hours after the last CY dose. VCR was repeated on day 11. Decadron 40 mg IV or orally was administered daily for 4 days on days 1 through 4 and 11 through 14. Granulocyte colony-stimulating factor (G-CSF) 5 pg/kg IV or subcutaneously was administered 24 hours after the end of DOX until the granulocyte count was greater than 4,500/pL. The second course was to commence immediately after clinical and hematologic recovery from the initial course. Treatment consisted of MTX 200 mg/m 2 IV bolus followed by a 24-hour MTX infusion of 800 mg/m 2 . This was followed by four doses of Ara-C 3,000 mg/m 2 administered at 12-hour intervals. Alkaline IV fluids were administered throughout. Folinic acid 50 mg was administered orally 24 hours after the end of the MTX infusion followed 6 hours later by 15 mg orally every 6 hours for eight doses. The dose was adjusted to the MTX level determined at 24 and 48 hours after the completion of MTX. G-CSF was administered at the same dose as after the first course. To reduce neurotoxicity for patients aged older than 60 years or if the serum creatinine level was greater than 1.5 mg/dL, Ara-C was decreased to 1,000 mg/m 2 IV per dose in these patients.
Courses were repeated every 21 days. Doses on subsequent courses were modified for a delay in hematologic recovery. For a delay of more than 7 days for thrombocytopenia, neutropenia, or serious infections, the CY, VCR, and DOX doses were reduced by 20%, the MTX dose by 25%, and the Ara-C dose by one third of the original doses. No changes were undertaken for the level of the nadir of the platelet or neutrophil counts even when transfusions were required. A reduction by 25% of the MTX dose was required if severe mucositis occurred with the prior MTX course, and by 50% if pleural effusion or ascites were present. Patients with greater than a 3-week delay in hematologic recovery were removed from the study.
Patients underwent re-evaluation after two and four courses of chemotherapy. Those aged 55 years or younger with an HLA-identical or a one antigen-mismatched related donor were to receive allogeneic stem-cell transplant. Those aged younger than 65 years who lacked an HLA-identical sibling were candidates to receive an autologous transplant provided that the bone marrow had less than 10% malignant cells on biopsy and less than 30% clonal cells by immunophenotyping. Unless eligible for allotransplantation, patients were removed from the study if they had progression of disease at any time or achieved less than a partial response (PR) after four courses.
Stem-Cell Transplantation
Peripheral-blood progenitor cells (PBPCs) were used for both autologous and allogeneic transplantation. Bone marrow was used if an adequate number of PBPCs could not be obtained (-2 x 106 CD34+ cells/kg). Autologous PBPCs were collected after recovery from the fourth course of conventional chemotherapy and restaging to determine the eligibility status. G-CSF 6 mg/kg subcutaneously every 12 hours was used for mobilization for both autologous or allogeneic transplant candidates. 7 Allogeneic hematopoietic cells were unfractionated. Selective CD34+ selection' s or immunomagnetic purging that used anti-CD19 monoclonal antibody was undertaken in eight patients who underwent autotransplantation.19 Because of the cell loss associated with these procedures, purging was only attempted if 3 X 0l cells/kg or greater were available in the bone marrow collection or 3 X 106 CD 34+ cells/kg or greater in peripheral blood. High-dose CY 60 mg/kg
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daily for 2 days and fractionated total-body irradiation 12.0 Gy over four fractions was used as the preparative regimen.
Supportive Care
While receiving the induction conventional-dose chemotherapy, patients were maintained on ciprofloxin 500 mg twice daily; fluconazole 200 mg daily; and acyclovir 200 mg twice daily. These prophylactic antibiotics were administered orally starting 24 hours after the end of chemotherapy until hematologic recovery. In addition, patients were administered sodium bicarbonate 1,300 mg twice daily and steroidcontaining eyedrops days 2 to 8 after each cycle of MTX-Ara-C. The supportive care after stem-cell transplantation was as previously described. 19 
Response Criteria
Complete response (CR) was defined as the disappearance of all clinical evidence of lymphoma for a minimum of 4 weeks with no symptoms related to the disease. When feasible, biopsy of any residual mass was recommended. Residual masses were required to be unchanged for 6 months or longer off treatment to be considered a CR. PR was defined as a greater than 50% decrease in the sum of the products of the diameters of all measured lesions that persisted for at least 4 weeks and nonmeasurable lesions had to decrease by at least 50%. No lesions could increase in size and no new lesions could appear. Progressive disease was defined as any increase of greater than 25% in the sum of the products of the diameters of any measurable lesions or the appearance of a new lesion.
Statistical Methods
Survival and disease progression of all patients were measured from the time of study entry. Event-free survival (EFS) was measured from entry onto the protocol until death or progressive disease. Survival and EFS function were estimated by the Kaplan-Meier method.
2 0 The log-rank test was used to test the null hypothesis that survivor functions were identical for the groups being compared. The statistical programming packages SAS (SAS Institute Inc, Cary, NC) and S-Plus (Statistical Science Inc, Seattle, WA) were used for analyses.
RESULTS
Patients
Between March 1994 and April 1997, 45 patients were registered. Patient characteristics are listed in Table 1 . Patient age ranged from 41 to 65 years, with a median of 55 years. Men predominated (39 men and six women). All had advanced lymphoma; 43 patients had stage IV disease, 41 patients had bone marrow involvement, and 10 patients had peripheral-blood involvement at the time of protocol entry. Twenty-five patients were newly diagnosed. One patient had superior vena cava syndrome that required emergency mediastinal radiotherapy. Gastrointestinal involvement occurred in 13 patients either as localized disease or as disseminated disease throughout the bowel.
Historic Control Group
Twenty-five newly diagnosed patients aged 65 years or younger treated at M.D. Anderson Cancer Center between 1986 and 1992 for stage IV diffuse (21 patients) and nodular (four patients) MCL with CHOP-like regimens comprised a historic control group for the 25 previously untreated patients who received Hyper-CVAD/MTX-Ara-C and were candidates for stem-cell transplantation in first remission. The characteristics of these two groups are listed in Table 2 .
Pathology
Histologic examination showed a diffuse growth pattern in 41 patients, nodular in two patients, and blastic cytology in two patients. Immunophenotypic analysis confirmed a monotypic B-cell population with coexpression of the CD5 antigen in 92% of the cases.
light chain expression predominated (55%). Cyclin Dl expression was identified in all but one of the 45 cases studied.
Stem-Cell Mobilization
Autologous peripheral-blood stem-cell mobilization that used G-CSF was attempted in 29 patients who were candidates for transplantation. Nine patients (31%) did not achieve an adequate collection of progenitors. Adequate CD34+ cells were collected in one patient after the addition of granulocyte-macrophage colony-stimulating factor. One patient had hypocellular marrow, and mobilization with Abbreviations: SCT, stem-cell transplantation; NS, not significant.
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G-CSF and later with G-CSF and CY failed. Six patients subsequently underwent bone marrow collection; an adequate number of stem cells were obtained in five patients. Ten patients had their autologous cells purged; eight patients with anti-CD19 antibody and two patients with CD34+ selection.
Response
Forty-five patients aged 65 years and younger were entered with the intention of transplantation. After four courses of induction chemotherapy, 17 patients (38%) achieved CRs and 25 patients (55.5%) had PRs.
Eleven patients did not receive the planned autologous transplant. One was not approved by his medical insurance carrier. Stem-cell collection failed in three patients. Three patients had progressive disease while they received Hyper-CVAD/MTX-Ara-C. One progressed before he received high-dose chemotherapy, and three declined a transplant procedure. Thirty-four patients underwent transplantation; 26 autologous and eight allogeneic. CR was achieved in all patients, which included those who were in PR after four cycles of Hyper-CVAD/MTX-Ara-C.
Eight patients underwent allotransplantation. Four patients were previously treated; induction failed in two patients, a prior autotransplantation failed in one patient, and four patients were previously untreated and were in first remission. Six patients were in PR at transplantation, and two patients were in CR. All achieved remission. Two died of chronic graft-versus-host disease (GVHD) while they were in CR at 7 and 10 months; no patient developed relapse.
EFS and Survival
The EFS rate for all patients at 3 years was 42% (95% confidence interval [CI], 14 to 70) and the probability of survival rate (OS) was 56% (95% CI, 22 to 89).
There was a significant difference in EFS and OS when patients with prior treatment versus those previously untreated were compared. For the previously untreated patients, the EFS rate (Fig 2) at 3 years was 72% (95% CI, 45 to 98) compared with 17% (95% CI, 10 to 43) in previously treated patients (P = .007). The OS rate (Fig 3) at 3 years was 92% (95% CI, 80 to 100) and 25% (95% CI, 12 to 62), respectively, in favor of the untreated patients (P = .005). Median follow-up of the untreated group was 25 months (range, 6.7 to 44.2 months) and 16.3 months (range, 6.7 to 48.7 months) for the previously treated group.
Both EFS and OS rates at 3 years for the patients who underwent allogeneic transplantation were 73% (95% CI, 41 to 100) compared with a 28% EFS rate (95% CI, 14 to 70%; P = .29) and a 48% OS rate (95% CI, 17 to 100%; P = .83) for the autotransplantation group (Figs 4 and 5 ). Median follow-up for the allotransplantation group was 27.7 months (range, 17.2 to 41.9 months). All three failures that occurred in the previously untreated patients were because of relapse. One patient had recurrent disease while receiving induction chemotherapy, and two other failures occurred after transplantation. One of these two patients was in CR and one in PR at the time of transplantation.
The cause of treatment failure in the previously treated patients was related to toxicity in three patients, GVHD postallotransplantation in two patients, and relapse in six patients. One relapse occurred in a patient while receiving his third course of induction chemotherapy; two other patients in whom peripheral-blood stem-cell mobilization failed relapsed while they were maintained on Hyper-CVAD/ MTX-Ara-C. Three other patients had recurrent disease after transplantation; two were in CR and one in PR at the time of transplantation.
Comparison With Historic Controls
The outcome for previously untreated patients was compared with that of equivalent patients who received CHOPlike chemotherapy at M.D. Anderson between 1986 and 1992. The control group had an EFS probability at 3 years of 28% (95% CI, 10 to 46; P = .0001; Fig 6) and survival rate of 56% (95% CI, 36 to 75; P = .05; Fig 7) .
Toxicity
All patients had reversible grade 4 neutropenia. Grade 4 thrombocytopenia occurred in 85% of the patients while receiving MTX-Ara-C and in 46% of the patients while receiving Hyper-CVAD. Discontinuation of therapy occurred in only one patient after course no. 3, secondary to persistent thrombocytopenia of more than 3 weeks. This same patient had sepsis with Torulopsis glabrata infection with course no. 2 that required a reduction of the doses of his third cycle of chemotherapy. Dose adjustments also were applied to three other patients; one after course no. 2 because of neutropenic fever associated with a delay of neutrophil recovery to 31 days, one after course no. 3, and one after course no. 4 because of a delay of adequate platelet recovery by 10 days.
Severe mucositis occurred in one patient who lost his uvula during course no. 4. One patient had vocal cord paresis that prompted the elimination of VCR from course no. 3. Most serious infections occurred after course no. 4: three cases of pneumonia were documented; one was caused by Aspergillus organisms and two were idiopathic. One patient developed a perirectal abscess, and one patient had cytomega- lovirus sinusitis. All infections responded to therapy before the initiation of high-dose chemoradiotherapy. Acute grade 2 GVHD that involved the skin occurred in three patients who received allogeneic transplants. This evolved to chronic extensive GVHD and contributed to the death of two patients. One received a one HLA antigenmismatched transplant and developed fungal pneumonia and hemolytic uremic syndrome. Another patient died of extensive GVHD and secondary pneumonitis 16 months after a T-cell-depleted allogeneic bone marrow transplantation performed at another institution.
Three patients died post-autologous transplantation. Two patients developed idiopathic pneumonitis and parainfluenza pneumonia at 3 and 2 months posttransplantation, respectively. One developed secondary myelodysplasia. Two patients failed to have platelet recovery postautotransplantation; one patient had human herpes virus-6 infection and has recovered after foscarnet and intravenous immunoglobulin therapy. There were two cases of fungal infection and one patient developed alpha-hemolytic Streptococcus infection; all recovered with appropriate therapy.
DISCUSSION
MCL shows architectural patterns that range from mantle zone appearance to nodular to purely diffuse. This heteroge- addressed outcome as a function of histologic pattern in a population of 46 previously untreated patients. Patients with mantle zone pattern had a CR rate of 75% and 3-year survival and freedom from disease progression rates of 100% and 83%, respectively. In contrast, MCL with a diffuse pattern had only a 20% CR rate and 3-year survival and freedom from disease progression rates of 55% and 26%, respectively. Similar poor outcome was suggested for patients with the nodular form. Blastic morphology has been associated with poor survival in two other studies.
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Therefore, it has been proposed that MCLs of mantle zone configuration be regarded as indolent lymphomas for purposes of clinical management, and that cases with diffuse, nodular, and blastic features be considered clinically aggressive tumors. The outcome of treatment for these aggressive MCLs has been consistently poor in all published series.
9 Novel treatment regimens are needed and the role of autologous and allogeneic hematopoietic transplantation needs to be established.
-
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A Pediatric Oncology Group Study used fractionated CY with DOX and VCR that alternated with sequential MTX and Ara-C in patients with B-cell ALL and stage IV small noncleaved-cell lymphoma. The CR rate was 93%, with improved EFS. This was confirmed by Kantarjian et al' 4 for adult patients with ALL. In this study, we evaluated this regimen as front-line therapy for patients with MCL. Given the poor prognosis of these patients, we opted to consolidate their response with stem-cell transplantation. In this study, pretransplantation treatment with four courses of Hyper-CVAD/MTX-Ara-C induced significant tumor regression in 93.5% (38% CRs) of the patients with poor-prognosis MCL, some of whom were previously treated. Although a high CR rate of 58% has also been reported with CHOP chemotherapy in 26 patients by Meusers et al, 24 the histologic variants in that study were not clearly defined, all patients were newly diagnosed, and, most important, the median disease-free survival was only 7 months. At the M.D. Anderson Cancer Center, only 20% of newly diagnosed patients with diffuse or nodular MCL achieved CR with a CHOP-like regimen. 1 In addition, a recent study by Freedman et a1 25 showed that after six to eight cycles of CHOP, only one of eight previously untreated patients with MCL achieved a CR in preparation for autologous bone marrow transplantation. The CR rate was 20% in 20 previously treated patients after a median of three chemotherapeutic regimens. The investigators acknowledged that better induction chemotherapy may improve the results of autotransplantation. These data indicate that the
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Hyper-CVAD/MTX-Ara-C regimen is promising as cytoreductive therapy for MCL. Controlled trials are needed to make definite conclusions regarding its activity compared with other regimens. Our treatment plan for MCL involved two innovations: induction with Hyper-CVAD/MTX-Ara-C and consolidation with stem-cell transplantation. Few long-term remissions or cures have been reported with conventional chemotherapy, 9 even in those patients who achieved CR. 26 Because of this, high-dose chemotherapy has been advocated for these patients. By the end of the treatment program in this study, all patients who were treated with allogeneic or autotransplantation achieved CR. Five deaths occurred, all in previously treated patients. Three deaths occurred after autotransplantation secondary to infection; one of these three patients developed myelodysplasia posttransplantation. One failed to recover his platelets despite receiving an adequate number of autologous stem cells. Two of the eight patients who received allogeneic transplants died of GVHDrelated complications. Better outcome in both EFS and OS has been reached in previously untreated patients compared with the group who had prior chemotherapy. Both groups had similar characteristics at the time of study entry. It is encouraging that this improvement in EFS and OS for the previously untreated group in our study is also evident when compared against a historic control group who received conventional therapy. At 3 years, the probability of EFS was 73% for the study group compared with 28% for the controls (P =.0001), and the OS rate was 73% and 56%, respectively (P =.05).
Of the 29 patients considered for autotransplantation, nine patients (31%) failed to have adequate peripheral stem-cell mobilization using G-CSF alone after four cycles of Hyper-CVAD/MTX-Ara-C. When compared with patients with other subtypes of non-Hodgkin's lymphomas who were mobilized with chemotherapy in addition to G-CSF at our institution, patients with MCL required double the median blood volume apheresed (46 v 21.5 L) and had a lower frequency of CD34+/L (9.57 v 44.84 x 10 6 /L). This suggests that newer cytokine combinations or chemotherapy should be studied to enhance stem-cell mobilization in this patient population. Encouraging results were obtained with allogeneic transplantation despite the poor prognostic features of these patients. Four of the eight allotransplantations occurred in previously treated patients, of whom induction failed in two and prior autotransplantation failed in one. Six were in PR after four cycles of Hyper-CVAD/MTX-Ara-C. One patient had blastic cytology. All patients achieved CR and none have relapsed. Allogeneic transplantation appears to be associated with a lower risk of recurrence than autografts in
